Ameluz® (BF-200 ALA)

About Biofrontera

Biofrontera Inc. is a publicly traded, commercial-stage biopharma company dedicated to becoming a leading U.S. specialty dermatology firm. Founded in 2015 to commercialize the FDA-approved PDT drug Ameluz®, the company has since expanded its portfolio with the antibiotic Xepi® and is advancing a pipeline of PDT candidates for conditions like basal cell carcinoma and acne. With a leadership team combining deep dermatology expertise and commercial experience, Biofrontera aims to establish PDT as a standard of care while leveraging its nanoemulsion platform for future growth.

About Biofrontera

Biofrontera Inc. is a publicly traded, commercial-stage biopharma company dedicated to becoming a leading U.S. specialty dermatology firm. Founded in 2015 to commercialize the FDA-approved PDT drug Ameluz®, the company has since expanded its portfolio with the antibiotic Xepi® and is advancing a pipeline of PDT candidates for conditions like basal cell carcinoma and acne. With a leadership team combining deep dermatology expertise and commercial experience, Biofrontera aims to establish PDT as a standard of care while leveraging its nanoemulsion platform for future growth.

About Biofrontera

Biofrontera Inc. is a publicly traded, commercial-stage biopharma company dedicated to becoming a leading U.S. specialty dermatology firm. Founded in 2015 to commercialize the FDA-approved PDT drug Ameluz®, the company has since expanded its portfolio with the antibiotic Xepi® and is advancing a pipeline of PDT candidates for conditions like basal cell carcinoma and acne. With a leadership team combining deep dermatology expertise and commercial experience, Biofrontera aims to establish PDT as a standard of care while leveraging its nanoemulsion platform for future growth.

About Biofrontera

Biofrontera Inc. is a publicly traded, commercial-stage biopharma company dedicated to becoming a leading U.S. specialty dermatology firm. Founded in 2015 to commercialize the FDA-approved PDT drug Ameluz®, the company has since expanded its portfolio with the antibiotic Xepi® and is advancing a pipeline of PDT candidates for conditions like basal cell carcinoma and acne. With a leadership team combining deep dermatology expertise and commercial experience, Biofrontera aims to establish PDT as a standard of care while leveraging its nanoemulsion platform for future growth.

About Biofrontera

Biofrontera Inc. is a publicly traded, commercial-stage biopharma company dedicated to becoming a leading U.S. specialty dermatology firm. Founded in 2015 to commercialize the FDA-approved PDT drug Ameluz®, the company has since expanded its portfolio with the antibiotic Xepi® and is advancing a pipeline of PDT candidates for conditions like basal cell carcinoma and acne. With a leadership team combining deep dermatology expertise and commercial experience, Biofrontera aims to establish PDT as a standard of care while leveraging its nanoemulsion platform for future growth.

About Biofrontera

Biofrontera Inc. is a publicly traded, commercial-stage biopharma company dedicated to becoming a leading U.S. specialty dermatology firm. Founded in 2015 to commercialize the FDA-approved PDT drug Ameluz®, the company has since expanded its portfolio with the antibiotic Xepi® and is advancing a pipeline of PDT candidates for conditions like basal cell carcinoma and acne. With a leadership team combining deep dermatology expertise and commercial experience, Biofrontera aims to establish PDT as a standard of care while leveraging its nanoemulsion platform for future growth.

About Biofrontera

Biofrontera Inc. is a publicly traded, commercial-stage biopharma company dedicated to becoming a leading U.S. specialty dermatology firm. Founded in 2015 to commercialize the FDA-approved PDT drug Ameluz®, the company has since expanded its portfolio with the antibiotic Xepi® and is advancing a pipeline of PDT candidates for conditions like basal cell carcinoma and acne. With a leadership team combining deep dermatology expertise and commercial experience, Biofrontera aims to establish PDT as a standard of care while leveraging its nanoemulsion platform for future growth.

Therapeutic Areas